Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET INSIGHTS
4.1 Market Overview
4.2 Industry Attractiveness - Porter’s Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Consumers
4.2.3 Threat of New Entrants
4.2.4 Threat of Substitutes
4.2.5 Intensity of Competitive Rivalry
4.3 Impact of COVID-19 on the 3D Bioprinting Market


5 MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Geriatric Population
5.1.2 Increasing Investments in R&D
5.2 Market Challenges
5.2.1 Operational Challenges


6 MARKET SEGMENTATION
6.1 By Technology
6.1.1 Syringe/Extrusion Bioprinting
6.1.2 Inkjet Bioprinting
6.1.3 Magnetic Levitation Bioprinting
6.1.4 Laser-assisted Bioprinting
6.1.5 Other Technologies
6.2 By Component
6.2.1 3D Bioprinters
6.2.2 Biomaterials
6.2.3 Scaffolds
6.3 By Application
6.3.1 Drug Testing and Development
6.3.2 Regenerative Medicine
6.3.3 Food Testing
6.3.4 Research
6.3.5 Other Applications
6.4 By Geography
6.4.1 North America
6.4.1.1 United States
6.4.1.2 Canada
6.4.2 Europe
6.4.2.1 United Kingdom
6.4.2.2 Germany
6.4.2.3 France
6.4.2.4 Rest of Europe
6.4.3 Asia-Pacific
6.4.3.1 China
6.4.3.2 Japan
6.4.3.3 India
6.4.3.4 Rest of Asia-Pacific
6.4.4 Rest of the World


7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Cellink
7.1.2 3D Systems Corporation
7.1.3 3D Bioprinting Solutions
7.1.4 REGEMAT 3D
7.1.5 Aspect Biosystems Ltd
7.1.6 Cyfuse Biomedical KK
7.1.7 Envision TEC GmbH
7.1.8 Organovo Holdings Inc.
7.1.9 RegenHU SA
7.1.10 Stratasys Ltd
7.1.11 GeSIM GmbH
7.1.12 Arcam AB (GE Company)


8 INVESTMENT ANALYSIS


9 FUTURE OF THE MARKET